Prices are updated after-hours

Health Technology 2021 - 02 - 11

Timber Pharmaceuticals, Inc.

TMBR | $0.3426 -2.69% 3K

(0.0% 1d) (0.0% 1m) (-75.9% 1y) (0.0% 2d) (0.0% 3d) (1.4% 7d) (-100.0% volume)
Earnings Calendar:
Market Cap: $ 1,176,055
http://www.timberpharma.com/
Sec Filling | Patents | 3 employees

(US) Timber Pharmaceuticals, Inc. operates as a biopharmaceutical company, which focuses on the development and commercialization of treatments for orphan dermatologic diseases. Its initial focus on developing non-systemic treatments for rare dermatologic diseases, including congenital ichthyosis, tuberous sclerosis complex and localized scleroderma. The company is headquartered in Woodcliff Lake, NJ.

sclerosis msa treatment

add to watch list Paper trade email alert is off

Acer Therapeutics Inc.

ACER | $0.9 -3.61% 420K

Health Technology

(0.0% 1d) (0.0% 1m) (3.5% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (1077.06% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 22,017,353
http://www.acertx.com
Sec Filling | Patents | 17 employees

(US) Acer Therapeutics, Inc. is a pharmaceutical company. The firm engages in the acquisition, development and commercialization of therapies for medical needs. Its product pipeline includes Edsivo and ACER-001. The Edsivo is a type of celiprolol for Vascular Ehlers-Danlos syndrome. The ACER-001 is for the treatment of urea cycle disorders and Maple Syrup Urine diseases. The company was founded by Christopher Schelling on September 19, 2017 and is headquartered in Newton, MA.

acquisitions urine urea treatment

add to watch list Paper trade email alert is off

Diffusion Pharmaceuticals Inc.

DFFN 4 | $6.6 11.68% -34.32% 350K

Health Technology

(0.0% 1d) (0.0% 1m) (15.8% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (308.49% volume)
Earnings Calendar: 2022-11-10
Market Cap: $ 13,465,894
http://www.diffusionpharma.com
Sec Filling | Patents | 10 employees

(US) Diffusion Pharmaceuticals, Inc. is a clinical stage company, which engages in the development of treatment for life threatening conditions. It offers Trans Sodium Crocetinate. The company was founded by David G. Kalergis and John L. Gainer in 2001 and is headquartered in Charlottesville, VA.

treatment

add to watch list Paper trade email alert is off

Eargo, Inc.

EAR | $2.57 7.78% 200K

Health Technology

(0.0% 1d) (0.0% 1m) (-46.2% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (2984.13% volume)
Earnings Calendar: 2023-11-02
Market Cap: $ 53,385,286
http://www.eargo.com
Sec Filling | Patents | 239 employees

Eargo, Inc. develops next generation hearing aids and headsets solutions. It offers Eargomax, a new chip for maximum audio fidelity and noise reduction and Eargoplus a superior hearing technology designed for first time hearing aid users. The company was founded by Florent Michel, Raphael Michel and Daniel Shen on November 12, 2010 and is headquartered in San Jose, CA.

audio chip

add to watch list Paper trade email alert is off

Eiger BioPharmaceuticals, Inc.

EIGR | $1.725 -1.45% 140K

Health Technology

(0.0% 1d) (-69.1% 1m) (72.5% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (16.88% volume)
Earnings Calendar: 2023-08-10
Market Cap: $ 2,554,375
http://www.eigerbio.com
Sec Filling | Patents | 24 employees

Eiger BioPharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization drugs for life-threatening, rare and ultra-rare diseases with high unmet medical needs and no approved therapies. The company was founded by David A. Cory and Glenn S. Jeffrey on November 6, 2008 and is headquartered in Palo Alto, CA.

Drugs

Zokinvy (lonafarnib)

add to watch list Paper trade email alert is off

Endo International plc

ENDP | News | $0.2926 -9.6%

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (-5.0% 3d) (0.0% 7d) (97.63% volume)
Earnings Calendar: 2022-11-03
Market Cap: $ 68,802,809
http://www.endo.com
Sec Filling | Patents | 3172 employees

Endo International Plc operates as a pharmaceutical company. It focuses on developing, manufacturing, and distributing of branded and generic pharmaceutical products. The firm operates through the following segments: U.S. Branded-Specialty & Established Pharmaceuticals, U.S. Branded-Sterile Injectables, U.S. Generic Pharmaceuticals and International Pharmaceuticals. The U.S. Branded-Specialty & Established Pharmaceuticals segment offers prescription products to treat and manage conditions in urology, urologic oncology, endocrinology, pain and orthopedics. The U.S. Branded-Sterile Injectables segment consists primarily of branded sterile injectable products such as VASOSTRICT, ADRENALIN and APLISOL, among others, and certain generic sterile injectable products, including ertapenem for injection and ephedrine sulfate injection, among others. The U.S. Generic Pharmaceuticals segment consists of a differentiated product portfolio including solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmics and sprays and includes products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health and cardiovascular disease markets, among others. The International Pharmaceuticals segment includes a variety of pharmaceutical products for the Canadian, Latin American, South African, and world markets. The company was founded in 1997 and is headquartered Dublin, Ireland.

cardiovascular women health nervous system women brands msa injection

add to watch list Paper trade email alert is off

Brickell Biotech, Inc.

BBI | $2.12 16.04%

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-74.2% volume)
Earnings Calendar: 2022-11-08
Market Cap: $ 6,092,806
http://www.brickellbio.com
Sec Filling | Patents | 15 employees

(US) Brickell Biotech, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. Its pipeline consists of new molecular entities targeting the treatment of the following indications: hyperhidrosis, allergic contact dermatitis, androgenic alopecia, cutaneous t-cell lymphoma and psoriasis. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in 2009 and is headquartered in Boulder, CO.

dermatitis skin t-cell treatment ceiling

add to watch list Paper trade email alert is off

Applied Genetic Technologies Corporation

AGTC | News | $0.3936 1.23% 0.0%

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-80.43% volume)
Earnings Calendar: 2022-11-08
Market Cap:
http://www.agtc.com
Sec Filling | Patents | 83 employees

(US) Applied Genetic Technologies Corp. is a clinical stage biotechnology company, which engages in the development of gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. It has clinical trials in the field of ophthalmology, optogenetics, adrenoleukodystrophy, and otology. The company was founded by Richard Jude Samulski, Nicholas Muzyczka, William W. Hauswirth, Terence R. Flotte, and Barry J. Byrne on January 19, 1999 and is headquartered in Alachua, FL.

gene therapies genetic clinical trials

add to watch list Paper trade email alert is off

ChemoCentryx, Inc.

CCXI | News | $51.99 -0.04%

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (160.14% volume)
Earnings Calendar: 2022-11-08
Market Cap: $ 3,709,791,785
http://www.chemocentryx.com
Sec Filling | Patents | 82 employees

(US) ChemoCentryx, Inc. is a biopharmaceutical company engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in Mountain View, CA.

cancer autoimmunity

add to watch list Paper trade email alert is off

Chinook Therapeutics, Inc.

KDNY | $40.39 0.22% -0.17% 0

Health Technology

(0.0% 1d) (0.0% 1m) (83.6% 1y) (0.0% 2d) (0.2% 3d) (0.0% 7d) (-30.62% volume)
Earnings Calendar: 2023-11-09
Market Cap: $ 2,900,203,021
http://www.chinooktx.com
Sec Filling | Patents | 96 employees

(US) Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA.

kidney diseases kidney

add to watch list Paper trade email alert is off

Clovis Oncology, Inc.

CLVS | $0.0812 -3.94%

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (26.22% volume)
Earnings Calendar: 2023-02-22
Market Cap: $ 11,770,367
http://www.clovisoncology.com
Sec Filling | Patents | 484 employees

Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of cancer treatments. Its marketed product Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is offered for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer; and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.

acquisitions cancer prostate cancer liver treatment cancer treatments

Drugs

Rubraca (rucaparib)

add to watch list Paper trade email alert is off

Codiak BioSciences, Inc.

CDAK | $0.057 -55.99% -131.25% 0

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-0.9% volume)
Earnings Calendar: 2022-11-03
Market Cap: $ 2,099,289
http://www.codiakbio.com
Sec Filling | Patents | 105 employees

(United States) Codiak BioSciences, Inc. engages in the development and manufacturing of exosomes. It engages in harnessing exosomes, therapeutic applications, diagnostic applications, and proprietary production. The firm develops engEx Platform, a proprietary and versatile exosome engineering and manufacturing platform, to expand upon the innate properties of exosomes to design novel exosome therapeutics. The company was founded by Douglas E. William, Raghu Kalluri, and Eric S. Lander in 2015 and is headquartered in Cambridge, MA.

diagnostics

add to watch list Paper trade email alert is off

Axcella Health Inc.

AXLA | $4.58 -56.33% 42K

Health Technology

(0.0% 1d) (0.0% 1m) (965.4% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (1982.28% volume)
Earnings Calendar: 2023-10-31
Market Cap: $ 13,500,512
http://www.axcellahealth.com
Sec Filling | Patents | 64 employees

Axcella Health, Inc. is a biotechnology company, which engages in the research and development of novel multifactorial interventions to support health and address dysregulated metabolism across a broad spectrum of consumers and patients who have limited options. Its product pipeline includes AXA1665, AXA1125, AXA1957, AXA2678, and AXA4010. The company was founded by Noubar B. Afeyan, Geoffrey von Maltzahn, and David A. Berry on August 27, 2008 and is headquartered in Cambridge, MA.

metabolic

add to watch list Paper trade email alert is off

AgeX Therapeutics, Inc.

AGE 4 | $11.1 0.0% 3.8K

Health Technology

(0.0% 1d) (-11.9% 1m) (1607.7% 1y) (0.0% 2d) (2.2% 3d) (-11.9% 7d) (-14.98% volume)
Earnings Calendar:
Market Cap: $ 27,757,370
http://www.agexinc.com
Sec Filling | Patents | 17 employees

(US) AgeX Therapeutics, Inc. operates as a biotechnology company. The firm focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases. Its technology platforms include PureStem, UniverCyte, iTR and HyStem. The company was founded by Michael D. West in 2017 and is headquartered in Alameda, CA.

msa

add to watch list Paper trade email alert is off

Compugen Ltd.

CGEN | $2.03 3.57% 3.45% 450K

Health Technology

(0.0% 1d) (-9.5% 1m) (281.7% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-100.0% volume)
Earnings Calendar: 2023-11-07
Market Cap: $ 181,152,054
http://www.cgen.com
Sec Filling | Patents | 61 employees

Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses its research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel.

antibody autoimmunity monoclonal antibodies israel diagnostics

add to watch list Paper trade email alert is off

ContraFect Corporation

CFRX | $0.05 0.0% 910K

Health Technology

(0.0% 1d) (0.0% 1m) (-96.8% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (2396.14% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 535,240
http://www.contrafect.com
Sec Filling | Patents | 24 employees

(US) ContraFect Corp. is a clinical stage biotechnology company, which engages in discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases. Its pipeline consists of CF-301, a bacteriophage-derived lysin with potent activity against Staphylococcus aureus bloodstream infections; and CF-404, which composed of three fully human monoclonal antibodies designed to treat all seasonal strains of human influenza. The company was founded by Robert Nowinski on March 5, 2008 and is headquartered in Yonkers, NY.

antibody monoclonal antibodies infectious disease influenza treatment bloodstream injection

add to watch list Paper trade email alert is off

Albireo Pharma, Inc.

ALBO | $44.15 -0.23% 0.39% 1.2M

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-100.0% volume)
Earnings Calendar: 2023-02-28
Market Cap: $ 913,961,644
http://www.albireopharma.com
Sec Filling | Patents | 55 employees

(US) Albireo Pharma, Inc. engages in the development and commercialization of bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. It pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.

gastrointestinal liver liver disease treatment odevixibat

add to watch list Paper trade email alert is off

Forward Pharma A/S

FWP | $1.95 7.74% 7.18%

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-64.55% volume)
Earnings Calendar:
Market Cap: $ 13,827,811
http://www.forward-pharma.com
Sec Filling | Patents | 5 employees

(DK) Forward Pharma A/S is a biopharmaceutical company, which engages in the research and development of medicinal treatment for inflammatory and neurological indications. It focuses on the immunomodulatory compound dimethyl fumarate and its derivatives. The company was founded by Florian Schönharting on July 1, 2005 and is headquartered in Copenhagen, Denmark.

neurological treatment

add to watch list Paper trade email alert is off

Genocea Biosciences, Inc.

GNCA | $0.051

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (-15.0% 3d) (0.0% 7d) (-35.74% volume)
Earnings Calendar: 2022-08-04
Market Cap:
http://www.genocea.com
Sec Filling | Patents | 59 employees

(US) Genocea Biosciences, Inc. engages in the development and commercialization of cancer vaccines. It uses its proprietary technology platform ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-003, an investigational immunotherapy for the treatment of genital herpes; and GEN-009, a neoantigen cancer vaccine. The company was founded by Robert Paull and Kevin J. Bitterman on August 16, 2006 and is headquartered in Cambridge, MA.

vaccine cancer immunotherapy t-cell genetic treatment ceiling

add to watch list Paper trade email alert is off

LogicBio Therapeutics, Inc.

LOGC | $2.07 -0.48%

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (-0.5% 7d) (NaN% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 68,232,857
http://www.logicbio.com
Sec Filling | Patents | 41 employees

(US) LogicBio Therapeutics, Inc. is a genome editing company, which engages in developing medicines to treat rare diseases in patients with significant unmet medical need. It focuses on the commercialization of specific genome editing and integration of the therapeutic transgene. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Cambridge, MA.

genomic genome editing

add to watch list Paper trade email alert is off